PREVENTIVE AGENT OR THERAPEUTIC AGENT FOR DISEASE CAUSED BY ABNORMAL BONE METABOLISM
申请人:Teijin Pharma Limited
公开号:EP2177219A1
公开(公告)日:2010-04-21
An object of the present invention is to provide a preventive drug and a therapeutic drug for diseases caused by abnormal bone metabolism, especially osteoporosis, which is more effective than conventional drugs. Combined use of N-hydroxy-4-5-[4-(5-isopropyl-2-methyl-1,3-thiazol-4-yl)phenoxy]pentoxy}-benzamidine, or a salt thereof; and at least one compound selected from the group consisting of etidronic acid, clodronic acid, pamidronic acid, tiludronic acid, risedronic acid, minodronic acid, ibandronic acid, zoledronic acid, and salts thereof can exert higher bone resorption inhibitory effect and provide a preventive effect and a therapeutic effect for diseases caused by abnormal bone metabolism, especially osteoporosis as compared with administration of the respective agents respectively.
本发明的目的是针对骨代谢异常引起的疾病,特别是骨质疏松症,提供一种比常规药物更有效的预防药物和治疗药物。联合使用 N-羟基-4-5-[4-(5-异丙基-2-甲基-1,3-噻唑-4-基)苯氧基]戊氧基}-苯甲脒或其盐;和至少一种选自由依替膦酸、氯膦酸、帕米膦酸、替鲁膦酸、利塞膦酸、米诺膦酸、伊班膦酸、唑来膦酸及其盐组成的组的化合物,可发挥更高的骨吸收抑制作用,并对骨代谢异常引起的疾病,特别是骨质疏松症提供预防效果和治疗效果。